Regulation of submaxillary gland androgenregulated protein 3A via estrogen receptor 2 in radioresistant head and neck squamous cell carcinoma cells

被引:12
作者
Gruenow, Jennifer [1 ,4 ]
Rong, Chao [1 ]
Hischmann, Jan [1 ]
Zaoui, Karim [1 ]
Flechtenmacher, Christa [2 ]
Weber, Klaus-Josef [3 ]
Plinkert, Peter [1 ]
Hess, Jochen [1 ,4 ]
机构
[1] Univ Heidelberg Hosp, Dept Otolaryngol Head & Neck Surg, Neuenheimer Feld 400, D-69120 Heidelberg, Germany
[2] Heidelberg Univ, Inst Pathol, Heidelberg, Germany
[3] Heidelberg Univ, Dept Radiat Oncol, Heidelberg, Germany
[4] German Canc Res Ctr, Res Grp Mol Mech Head & Neck Tumors, Heidelberg, Germany
来源
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | 2017年 / 36卷
关键词
ESR2; Estrogen; Fulvestrant; HNSCC; OPSCC; Radiotherapy; SMR3A; Tamoxifen; UNFAVORABLE RISK-FACTOR; BREAST-CANCER PATIENTS; LUNG-CANCER; TAMOXIFEN THERAPY; BETA EXPRESSION; IN-VITRO; ER-BETA; FULVESTRANT; SURVIVAL; PHOSPHORYLATION;
D O I
10.1186/s13046-017-0496-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Molecular mechanisms of intrinsic or acquired radioresistance serve as critical barrier for curative therapy of head and neck squamous cell carcinoma (HNSCC) and remain a major obstacle for progression-free and disease-specific survival. Methods: HNSCC cell lines were treated with a protocol of fractionated irradiation (IR,4X 2Gy)alone or in combination with antagonists of estrogen receptor signaling and viability was determined by a colony-forming assay (CFA). Expression of submaxillary gland androgen-regulated protein 3A (SMR3A) and estrogen receptor 2 (ESR2) were assessed in tumor cells in vitro by RQ-PCR, Western blot analysis and immunofluorescence staining, and by immunohistochemical staining of tissue microarrays containing tumor sections from patients with oropharyngeal squamous cell carcinoma (OPSCC), which were treated by definitive or adjuvant radiotherapy. Subgroups with distinct SMR3A and ESR2 expression patterns were correlated with clinical parameters and survival outcome including multivariable analysis. Results: Fractionated irradiation (IR) revealed an accumulation of tumor cells with prominent SMR3A expression, which was accompanied by an up-regulation of the estrogen receptor 2 (ESR2). ESR2-dependent regulation of SMR3A was supported by induced expression after stimulation with estradiol (E2), which was impaired by co-treatment with 4-Hydroxytamoxifen (TAM) or Fulvestrant, respectively. Both drugs significantly sensitized FaDu cells to fractionated IR as determined by a CFA and accelerated apoptosis. These data suggest a critical role of ESR2 in radioresistance and that SMR3A might serve as a surrogate marker for active ESR2 signaling. In line with this assumption, ESR2-positive oropharyngeal squamous cell carcinoma (OPSCC) with high SMR3A expression had an unfavorable progression-free and disease-specific survival as compared to those tumors with low SMR3A expression. Conclusions: In summary, our findings provide compelling experimental evidence that HNSCC with SMR3A and ESR2 co-expression have a higher risk for treatment failure and these patients might benefit from clinically well-established drugs targeting estrogen receptor signaling.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 38 条
  • [1] Targeting irradiation-induced mitogen-activated protein kinase activation in vitro and in an ex vivo model for human head and neck cancer
    Affolter, Annette
    Muller, Marie-France
    Sommer, Katharina
    Stenzinger, Albrecht
    Zaoui, Karim
    Lorenz, Katja
    Wolf, Thomas
    Sharma, Sarika
    Wolf, Janina
    Perner, Sven
    Weber, Klaus-Josef
    Freier, Kolja
    Plinkert, Peter K.
    Hess, Jochen
    Weichert, Wilko
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 : E2049 - E2061
  • [2] The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
    Barker, Holly E.
    Paget, James T. E.
    Khan, Aadil A.
    Harrington, Kevin J.
    [J]. NATURE REVIEWS CANCER, 2015, 15 (07) : 409 - 425
  • [3] Loss of SOX2 expression induces cell motility via vimentin up-regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma
    Bayo, Pilar
    Jou, Adriana
    Stenzinger, Albrecht
    Shao, Chunxuan
    Gross, Madeleine
    Jensen, Alexandra
    Grabe, Niels
    Mende, Christel Herold
    Rados, Pantelis Varvaki
    Debus, Juergen
    Weichert, Wilko
    Plinkert, Peter K.
    Lichter, Peter
    Freier, Kolja
    Hess, Jochen
    [J]. MOLECULAR ONCOLOGY, 2015, 9 (08) : 1704 - 1719
  • [4] Testosterone regulates erectile function and Vcsa1 expression in the corpora of rats
    Chua, Rowena G.
    Calenda, Giulia
    Zhang, Xinhua
    Siragusa, Joseph
    Tong, Yuehong
    Tar, Moses
    Aydin, Memduh
    DiSanto, Michael E.
    Melman, Arnold
    Davies, Kelvin P.
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2009, 303 (1-2) : 67 - 73
  • [5] Insight into the mechanisms of action of estrogen receptor β in the breast, prostate, colon, and CNS
    Dey, Prasenjit
    Barros, Rodrigo P. A.
    Warner, Margaret
    Stroem, Anders
    Gustafsson, Jan-Ake
    [J]. JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2013, 51 (03) : T61 - T74
  • [6] Doll C, 2015, ANTICANCER RES, V35, P5867
  • [7] Cross-Talk between Estrogen Receptor and Epidermal Growth Factor Receptor in Head and Neck Squamous Cell Carcinoma
    Egloff, Ann Marie
    Rothstein, Mary E.
    Seethala, Raja
    Siegfried, Jill M.
    Grandis, Jennifer Rubin
    Stabile, Laura P.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (21) : 6529 - 6540
  • [8] Ferlay J., GLOBOCAN 2012 V1 0
  • [9] Clonogenic assay of cells in vitro
    Franken, Nicolaas A. P.
    Rodermond, Hans M.
    Stap, Jan
    Haveman, Jaap
    van Bree, Chris
    [J]. NATURE PROTOCOLS, 2006, 1 (05) : 2315 - 2319
  • [10] Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma
    Freudlsperger, Christian
    Horn, Dominik
    Weissfuss, Sebastian
    Weichert, Wilko
    Weber, Klaus-Josef
    Saure, Daniel
    Sharma, Sarika
    Dyckhoff, Gerhard
    Grabe, Niels
    Plinkert, Peter
    Hoffmann, Juergen
    Freier, Kolja
    Hess, Jochen
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (12) : 2775 - 2785